Antibody-Drug Conjugates In Oncology: Key Considerations And Future Trends

By Ayesha Pandit

Antibody-drug conjugates (ADCs) are an active area of oncology research, partly due to advances in synthetic biochemistry that may help improve the tissue specificity and cytotoxicity of these complex therapeutics. In recent years, the pace of development for this class of cancer therapeutics has been increasing, with 12 ADCs  approved by the FDA since June 2019.

In this blog, we explore the current landscape of antibody-drug conjugates, including their benefits, limitations, key considerations for clinical trials, and potential future trends.